Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with <sup>18</sup>F-FLT.
Where this comes from
- Record sourced from PubMed, PMID 29217733.
- Also identified by DOI 10.2967/jnumed.117.199406 and PMC identifier 5932529.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The study objective was to investigate whether sex influences 3'-deoxy-3'-<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) uptake and tissue distribution in mouse models of cancer. <b>Methods:</b><sup>18</sup>F-FLT biodistribution was measured in 3 strains of male and female mice (129S6/SvEv, athymic nude, and BALB/c). <sup>18</sup>F-FDG biodistribution was measured for comparison. <sup>18</sup>F-FLT uptake was also measured in female 129S6/SvEv mice bearing estrogen-dependent SSM3 mouse mammary tumors, male athymic nude mice bearing androgen-dependent CWR22 prostate cancer xenografts, and male and female athymic nude mice bearing estrogen-independent MDA-MB-231 human breast cancer xenografts. Ki-67 expression was assayed by immunohistochemistry. PET/CT imaging was performed to visualize <sup>18</sup>F-FLT biodistribution and to determine pharmacokinetics. <b>Results:</b> Greater <sup>18</sup>F-FLT activity was observed in blood, liver, muscle, heart, kidney, and bone in female than male mice. Pharmacokinetic analysis demonstrated higher early renal <sup>18</sup>F-FLT activity and greater accumulation of <sup>18</sup>F-FLT in the urinary bladder in male than female mice. The differential pattern of <sup>18</sup>F-FLT biodistribution between the sexes seen with <sup>18</sup>F-FLT was not observed with <sup>18</sup>F-FDG. Increased tumoral <sup>18</sup>F-FLT uptake compared with muscle was observed in both the SSM3 mammary tumors (2.4 ± 0.17 vs. 1.6 ± 0.14 percentage injected dose [%ID]/g at 2 h after injection, <i>P</i> = 0.006) and the CWR22 prostate cancer xenografts (0.34 ± 0.08 vs. 0.098 ± 0.033 %ID/g at 2 h after injection, <i>P</i> = 0.03). However, because of higher nonspecific muscle uptake in female mice, tumor-to-muscle uptake ratios were greater for CWR22 tumors than for SSM3 tumors (4.2 ± 0.78 vs. 1.5 ± 0.049 at 2 h after injection, <i>P</i> = 0.008). Sex-dependent differences in <sup>18</sup>F-FLT uptake were also observed for MDA-MB-231 xenografts (tumor-to-muscle ratio, 7.2 ± 0.9 for female vs. 16.9 ± 8.6 for male, <i>P</i> = 0.039). Conversely, greater tumoral Ki-67 staining was observed in female mice (71% ± 3% for female vs. 54% ± 2% for male, <i>P</i> = 0.009), and this finding more closely matched the relative differences in absolute <sup>18</sup>F-FLT tumor uptake values (4.5 ± 0.99 %ID/g for female vs. 1.9 ± 0.30 %ID/g for male, <i>P</i> = 0.03). <b>Conclusion:</b> Depending on whether female or male mice are used, differences in biodistribution and nonspecific tissue uptake can adversely affect quantitative measures of <sup>18</sup>F-FLT uptake. Thus, sex is a potential variable to consider in defining quantitative imaging metrics using <sup>18</sup>F-FLT to assess tumor proliferation.
Medical subject headings
- Diagnostic Imaging
- Dideoxynucleosides
- Sex Factors